⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADIL News
Adial Pharmaceuticals, Inc
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
globenewswire.com
ADIL
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
globenewswire.com
ADIL
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
globenewswire.com
ADIL
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
ADIL
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
globenewswire.com
ADIL